Chimimpex Group
- Country:
Bulgaria - Year Established: 1993
- Business type: Lab/Research institutions
- Contact Details | Similar Products
You May Like:
Favipiravir ...... ! (T-705) ...... Avigan CAS NO.259793-96-9
- Min.Order Quantity:
- 10 Gram
- Purity:
- 98%
- Port:
- Europe
- Payment Terms:
- L/C,T/T,
Keywords
- Avigan
- Coronavirus
- COVID-19
Quick Details
- ProName: Favipiravir ...... ! (T-705) ...... A...
- CasNo: 259793-96-9
- Molecular Formula: C?H?FN?O?
- Appearance: Light yellow to yellow solid
- Application: Favipiravir T-705 Avigan
- PackAge: Fibre Drums
- Port: Europe
- ProductionCapacity: Kilogram/Month
- Purity: 98%
- Transportation: DHL
- LimitNum: 10 Gram
- Grade: Pharma Grade
Superiority
we offer
t-705 (favipiravir) is an antiviral drug that selectively inhibits the rna-dependent rna polymerase of influenza virus. it is phosphoribosylated by cellular enzymes to its active form, favipiravir-ribofuranosyl-5'-triphosphate (rtp). favipiravir is active against a broad range of influenza viruses, including a(h1n1)pdm09, a(h5n1) and the recently emerged a(h7n9) avian virus. it also inhibits influenza strains resistant to current antiviral drugs, and shows a synergistic effect in combination with oseltamivir, thereby expanding influenza treatment options. recently, t-705 has been shown to give 100% protection against aerosol ebola virus e718 infection in immune-deficient mice as well as inhibiting ebola virus infection in cell culture. it has been shown to inhibit sars-cov-2 in vitro.
usage: for research use only! not for use in humans.
Details
we offer
t-705 (favipiravir) is an antiviral drug that selectively inhibits the rna-dependent rna polymerase of influenza virus. it is phosphoribosylated by cellular enzymes to its active form, favipiravir-ribofuranosyl-5'-triphosphate (rtp). favipiravir is active against a broad range of influenza viruses, including a(h1n1)pdm09, a(h5n1) and the recently emerged a(h7n9) avian virus. it also inhibits influenza strains resistant to current antiviral drugs, and shows a synergistic effect in combination with oseltamivir, thereby expanding influenza treatment options. recently, t-705 has been shown to give 100% protection against aerosol ebola virus e718 infection in immune-deficient mice as well as inhibiting ebola virus infection in cell culture. it has been shown to inhibit sars-cov-2 in vitro.
usage: for research use only! not for use in humans.